An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced malignancies
A study for patients with diffuse large B-cell lymphoma using study drug BAY 1143572
Sponsor: Bayer Healthcare Pharmaceuticals Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ6929
U.S. Govt. ID: NCT01938638
Contact: Changchun Deng: 212-326-5720 / cd2448@columbia.edu
Additional Study Information: The purpose of the study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572 when taken with a drug to help the white blood cells in your blood (a drug called granulocyte colony-stimulating factor or G-CSF) in an intermittent or continuous once-daily dosing schedule in subjects with advanced cancers such as diffuse large B-cell lymphoma.
This study is closed
Investigator
Changchun Deng, MD, PhD
Do You Qualify?
Have you been diagnosed with any of the mentioned cancers? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Changchun Deng
cd2448@columbia.edu
212-326-5720
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE